nt cvd : development and validation of new diagnostic, preventive and therapeutic tools for the...
TRANSCRIPT
NTCVD: Development and Validation of new Diagnostic, Preventive and Therapeutic Tools for the Prevention of
Cardiovascular Disease in Chronic Kidney Disease
PRINCIPAL INVESTIGATORS
4 1
2
3
6
5
7
1. Prof. Dr. Jankowski, Dr. Jankowski, Charité, Medizinische Klinik IV, Berlin
2. Dr. Lehmann, PD Dr. Buschmann, Charité, Center for Cardiovascular Research, Berlin
3. PD Dr. Herget-Rosenthal, Universitätsklinikum Essen, Klinik für Nephrologie
4. Prof. Dr. Lehrach, Dr. Herwig, Max-Planck-Institut Berlin, Molecular Genetics
5. Dr. Lemke, EXcorLab GmbH, Obernburg6. Dr. Krahn, Bayer Schering Pharma, Wuppertal7. Associated Partner: Membrana GmbH, Wuppertal
Figure 1: Organization Chart of the Consortium■SME ■Clinic ■University ■Research Institute ■Industry ■Molecular Phenotyping ■Application Development – Work Package Partner – Work Package Leader → Informational Flow
SUMMARY
The consortium will apply the novel tools “proteomics, peptidomics,
metabonomics and genotyping”, which allow assessing the complete
transcription and translation of the genomic capital to elucidate the genetic
and physiological background of CVD in CKD patients. This approach is
focused on human samples i.e. tissues, cells and body fluids as humoral
targets are altered in CVD of CKD patients.
NTCVD applies "forward genetics" from phenotype to gene to remedy the
causes of the enormously accelerated cardiovascular morbidity and death
in CKD (stage 3-5) and to develop novel diagnostics and therapeutics,
based on molecular genotyping and phenotyping. This will be done (A)
by elucidating the role of recently identified mediators relating to CVD in
CKD by using bioassay approaches and pattern analysis of CKD patient
samples, and (B) by the identification of yet unknown mediators.
Figure 2: General approaches of NTCVD
Correspondence: Prof. Dr. Joachim Jankowski, Charité, Med Klinik IV, Hindenburgdamm 30, 12200 Berlin, Germany; [email protected]
Specific aims of NTCVD
Identify specific mediators, known and unknown, involved in .accelerated CVD in CKD Identify among these mediators specific predictive biomarkers of .accelerated CVD in CKD Identify specifically new therapeutic targets to combat accelerated .CVD in CKD Integration into a web accessible CKD knowledgebase Generate the scientific & technical basis for the development of .both pharmaceutical therapies & extracorporeal removal strategies Translate the results into new diagnostic, preventive and .therapeutic tools and devices
Overall aims of NTCVD
Prevention of CVD in CKD patients Translate diagnostic biomarkers and preventive approaches to .non-CKD population Remedy the causes of accelerated CVD in CKD Identify and characterize biomarkers for cardiovascular risk in .CKD patients Decrease therapy costs for CKD patients Decrease overall costs, socio-economic challenges and number of .patients Enhance German competitiveness in producing diagnostic and .therapeutic tools
CONCLUSION
This project aims to use proven and in some instances proprietary
molecular, genomic and proteomic approaches to identify and characterize
the unknown mediators potentially involved in the accelerated CVD in
CKD (stage 3-5). Furthermore the consortium will have to characterize
known mediators in detail with respect to their cardiovascular effects.
The findings and results will culminate in the conception and development
of innovative tools to diagnose, prevent and treat CVD in CKD patients.
COORDINATION: J. Jankowski (Charité) | CO-COORDINATION: T. Krahn (Bayer-Schering-Pharma)PARTNER: V. Jankowski, K. Lehmann (Charite) | H. Bruck (Universitätsklinikum Essen) |
R. Herweg (MPI MolGen) | H. Lemke (EXcorLab)